Gene Therapy Research Institution and Astellas executes option agreement for sporadic ALS gene therapy program

TOKYO, September 14, 2018 – Gene Therapy Research Institution Co., Ltd. (head office: Kawasaki, Kanagawa; President: Katsuhito Asai, “GTRI”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that they have entered into an option agreement for the exclusive negotiation of rights to global development and commercialization of the gene therapy program GT0001X for the treatment of sporadic amyotrophic lateral sclerosis (ALS).